VIVOSIM LABS INC (VIVS) Stock Price, Quote, News and Overview
NASDAQ:VIVS - Nasdaq - US68620A3023 - Common Stock - Currency: USD
VIVS Quote, Performance and Key Statistics
NASDAQ:VIVS (5/21/2025, 8:00:01 PM)
1.945
-0.08 (-4.19%)
The current stock price of VIVS is 1.945 USD.
VIVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About VIVS
Company Profile
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
Company Info
VIVOSIM LABS INC
Suite 100, 11555 Sorrento Valley Road
San Diego CALIFORNIA US
Employees: 20
Phone: 18582241000
VIVOSIM LABS INC / VIVS FAQ
What is the stock price of VIVOSIM LABS INC today?
The current stock price of VIVS is 1.945 USD. The price decreased by -4.19% in the last trading session.
What is the ticker symbol for VIVOSIM LABS INC stock?
The exchange symbol of VIVOSIM LABS INC is VIVS and it is listed on the Nasdaq exchange.
On which exchange is VIVS stock listed?
VIVS stock is listed on the Nasdaq exchange.
What is VIVOSIM LABS INC worth?
VIVOSIM LABS INC (VIVS) has a market capitalization of 3.31M USD. This makes VIVS a Nano Cap stock.
How many employees does VIVOSIM LABS INC have?
VIVOSIM LABS INC (VIVS) currently has 20 employees.
What are the support and resistance levels for VIVOSIM LABS INC (VIVS) stock?
VIVOSIM LABS INC (VIVS) has a support level at 1.88. Check the full technical report for a detailed analysis of VIVS support and resistance levels.
Is VIVOSIM LABS INC (VIVS) expected to grow?
The Revenue of VIVOSIM LABS INC (VIVS) is expected to grow by 126.67% in the next year. Check the estimates tab for more information on the VIVS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VIVOSIM LABS INC (VIVS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VIVS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VIVS, evaluating the profitability, health, valuation and growth aspects
- VIVOSIM LABS INC (VIVS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIVOSIM LABS INC (VIVS) Sales and EPS estimates to see what analysts future expectations are.
- VIVOSIM LABS INC (VIVS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIVOSIM LABS INC (VIVS) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIVOSIM LABS INC (VIVS) Stock Chart to make your own analysis
- VIVOSIM LABS INC (VIVS) Latest news and press-releases to stay up to date.
Does VIVOSIM LABS INC (VIVS) stock pay dividends?
VIVS does not pay a dividend.
What is the Price/Earnings (PE) ratio of VIVOSIM LABS INC (VIVS)?
VIVOSIM LABS INC (VIVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.49).
What is the Short Interest ratio of VIVOSIM LABS INC (VIVS) stock?
The outstanding short interest for VIVOSIM LABS INC (VIVS) is 8.73% of its float. Check the ownership tab for more information on the VIVS short interest.
VIVS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VIVS.
VIVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VIVS. While VIVS seems to be doing ok healthwise, there are quite some concerns on its profitability.
VIVS Financial Highlights
Over the last trailing twelve months VIVS reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 60.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -322.19% | ||
| ROE | -3402.47% | ||
| Debt/Equity | 0 |
VIVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to VIVS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 126.67% for VIVS